JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Saved in:
Main Authors: | Nobukazu Fujimoto, Yosuke Miyamoto, Sae Wada, Katsuyuki Hotta, Toshiyuki Kozuki, Keisuke Aoe, Jun Sakurai, Michihiro Yoshida, Daijiro Harada |
---|---|
Format: | article |
Language: | EN |
Published: |
BMJ Publishing Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/af8197ea96ff4fda8b8b228a37b81135 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
by: Cova E, et al.
Published: (2019) -
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
by: Hiroto Yoneda, et al.
Published: (2021) -
Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
by: Camillo Porta, et al.
Published: (2008) -
Cytomegalovirus infection in malignant pleural mesothelioma.
by: DeVon Hunter-Schlichting, et al.
Published: (2021) -
Modern management of malignant pleural mesothelioma
by: Patel SC, et al.
Published: (2016)